Lexaria Bioscience ‘applauds’ Eli Lilly’s Foundayo drug approval

Lexaria Bioscience (LEXX) is pleased to recognize that the US Food and Drug Administration has approved Eli Lilly and Company’s (LLY) Foundayo glucagon-like peptide-1 agonist oral tablet for adult use in controlling obesity and weight-related medical conditions. “This latest approval from the FDA expands choices for Americans searching for the right weight control drug that best suits their needs,” said Richard Christopher, CEO. “Expanded choices within the historically limited oral weight-loss drug category increases opportunities for Lexaria to partner with the leading companies in the pharmaceutical industry to implement DehydraTECH technology to improve patient experiences including through the potential for reduced side effects.”